Alpha 2.0
Login Register
» Articles » PMID: 2127345

Development of Quinolone-imipenem Cross Resistance in Pseudomonas Aeruginosa During Exposure to Ciprofloxacin

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 1990 Nov 1
PMID 2127345
Citations 22
Authors
G Radberg
L E Nilsson
S Svensson
Affiliations
Soon will be listed here.
Abstract

Selection and regrowth of ciprofloxacin-resistant variants, which were present in low frequencies in the initial inoculum, were seen when large inocula of Pseudomonas aeruginosa were incubated with ciprofloxacin. These variants showed cross resistance to other quinolones. In 8 of 13 strains tested, ciprofloxacin selected imipenem-resistant variants in a similar way to imipenem. The opposite phenomenon of ciprofloxacin-imipenem cross resistance after exposure to imipenem was not detected. None of the ciprofloxacin-resistant variants showed cross resistance to aztreonam, piperacillin, or tobramycin. These findings indicate that widespread and uncritical use of ciprofloxacin gives a potential risk of development of resistance in P. aeruginosa not only to quinolones but also to another unrelated useful agent, imipenem. In vitro evaluation of this phenomenon in isolates from patients with P. aeruginosa infections may be justified, since strains differ in development of quinolone-imipenem cross resistance after ciprofloxacin exposure.

Citing Articles

Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.

Hakki M, Humphries R, Hemarajata P, Tallman G, Shields R, Mettus R Clin Infect Dis. 2018; 68(12):2045-2052.

PMID: 30256922 PMC: 6541707. DOI: 10.1093/cid/ciy825.

The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna A, Al Shirawi N, Wali S Ann Thorac Med. 2017; 12(3):135-161.

PMID: 28808486 PMC: 5541962. DOI: 10.4103/atm.ATM_171_17.

Active efflux pump adeB is involved in multidrug resistance of induced by antibacterial agents.

Zhang T, Wang M, Xie Y, Li X, Dong Z, Liu Y Exp Ther Med. 2017; 13(4):1538-1546.

PMID: 28413506 PMC: 5377525. DOI: 10.3892/etm.2017.4141.

Benefits and unintended consequences of antimicrobial de-escalation: Implications for stewardship programs.

Hughes J, Huo X, Falk L, Hurford A, Lan K, Coburn B PLoS One. 2017; 12(2):e0171218.

PMID: 28182774 PMC: 5300270. DOI: 10.1371/journal.pone.0171218.

The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Li X, Plesiat P, Nikaido H Clin Microbiol Rev. 2015; 28(2):337-418.

PMID: 25788514 PMC: 4402952. DOI: 10.1128/CMR.00117-14.

References
1.
Barry A, Jones R . Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother. 1984; 25(6):775-7. PMC: 185641. DOI: 10.1128/AAC.25.6.775. View
2.
Sanders C, Sanders Jr W, Goering R, Werner V . Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984; 26(6):797-801. PMC: 180026. DOI: 10.1128/AAC.26.6.797. View
3.
Cullmann W, Stieglitz M, Baars B, Opferkuch W . Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants. Chemotherapy. 1985; 31(1):19-28. DOI: 10.1159/000238309. View
4.
Limb D, Dabbs D, Spencer R . In-vitro selection of bacteria resistant to the 4-quinolone agents. J Antimicrob Chemother. 1987; 19(1):65-71. DOI: 10.1093/jac/19.1.65. View
5.
Piddock L, Wijnands W, Wise R . Quinolone/ureidopenicillin cross-resistance. Lancet. 1987; 2(8564):907. DOI: 10.1016/s0140-6736(87)91387-0. View